Joint bone spine · 2026
Interleukin-33 drives abnormal bone remodeling in ankylosing spondylitis via inhibition of osteoclast differentiation.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Choi Se Rim, Lee Seung Hoon, Kim Dongju, Kim Dabhin, Wang Sung Eun, Youn Jeehee, Lee Seunghun, Jo Sungsin, Kim Tae-Hwan
Аннотация
OBJECTIVES: Interleukin (IL)-33 has been shown to be abnormally expressed in patients diagnosed with ankylosing spondylitis (AS). However, the source of IL-33 and the mechanism(s) through which IL-33 affects bone metabolism in AS remains unclear.
METHODS: Serum IL-33 levels were measured in patients diagnosed with AS and healthy controls (HCs). Primary human enthesis cells were isolated from surgically harvested human enthesis tissues to evaluate IL-33 expression under tumor necrosis factor (TNF) and IL-17A stimulation using bulk RNA sequencing and Western blotting. The therapeutic potential of IL-33 in curdlan-treated SKG mice to mimic AS was assessed using anti-IL-33 neutralizing antibodies. The effects of IL-33 on bone remodeling were further explored using osteoblast and osteoclast differentiation assays.
RESULTS: Serum IL-33 levels were significantly elevated in patients with AS with a high inflammatory burden and were positively correlated with TNF, IL-17A, and radiographic progression. In AS enthesis tissues and primary cells, IL-33 expression was markedly higher than that in HCs. Notably, synergistic stimulation by TNF and IL-17A significantly upregulated IL-33 at both the transcriptomic and protein levels, particularly in ASenthesis cells. In vivo, anti-IL-33 treatment significantly attenuated clinical arthritis severity, enthesitis scores, and enthesophyte formation in a mouse model of AS. Mechanistically, IL-33 significantly inhibited osteoclastogenesis by suppressing the p38 MAPK-NFATc1 signaling pathway in osteoclast precursors.
CONCLUSION: These findings demonstrate that IL-33 is a key mediator that links systemic inflammation to local enthesopathy and pathological bone formation in patients with AS. Accordingly, the IL-33/p38/NFATc1 axis may offer a crucial mechanistic link between osteoclasts and osteoblasts for understanding the pathological bone remodeling characteristics of AS.
METHODS: Serum IL-33 levels were measured in patients diagnosed with AS and healthy controls (HCs). Primary human enthesis cells were isolated from surgically harvested human enthesis tissues to evaluate IL-33 expression under tumor necrosis factor (TNF) and IL-17A stimulation using bulk RNA sequencing and Western blotting. The therapeutic potential of IL-33 in curdlan-treated SKG mice to mimic AS was assessed using anti-IL-33 neutralizing antibodies. The effects of IL-33 on bone remodeling were further explored using osteoblast and osteoclast differentiation assays.
RESULTS: Serum IL-33 levels were significantly elevated in patients with AS with a high inflammatory burden and were positively correlated with TNF, IL-17A, and radiographic progression. In AS enthesis tissues and primary cells, IL-33 expression was markedly higher than that in HCs. Notably, synergistic stimulation by TNF and IL-17A significantly upregulated IL-33 at both the transcriptomic and protein levels, particularly in ASenthesis cells. In vivo, anti-IL-33 treatment significantly attenuated clinical arthritis severity, enthesitis scores, and enthesophyte formation in a mouse model of AS. Mechanistically, IL-33 significantly inhibited osteoclastogenesis by suppressing the p38 MAPK-NFATc1 signaling pathway in osteoclast precursors.
CONCLUSION: These findings demonstrate that IL-33 is a key mediator that links systemic inflammation to local enthesopathy and pathological bone formation in patients with AS. Accordingly, the IL-33/p38/NFATc1 axis may offer a crucial mechanistic link between osteoclasts and osteoblasts for understanding the pathological bone remodeling characteristics of AS.